Latest Health News

Theta Gold Mines Limited has had its trading suspension lifted immediately following the release of a funding transaction announcement, signaling renewed market activity for the gold miner.

Seafarms Group Limited has resumed trading on the ASX following the lifting of its suspension, triggered by the lodgement of its annual financial report.

Assetora Limited has released its audited FY25 financial report showing a significant reduction in losses and a strengthened capital position, highlighted by the reopening of the DomaCom Fund and a $3 million private placement. The company aims to leverage these developments to accelerate growth in funds under management.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Jayride Group Limited’s shares have been suspended from trading on the ASX following concerns over its financial health and a critical auditor’s disclaimer. The suspension highlights significant regulatory scrutiny and investor risk.

Eildon Capital Group has updated investors on a default notice issued to the borrower at Kings-Newport Village, emphasizing that the default relates to a site outside its secured loan facility.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.

Turners Automotive Group Limited has announced a fully franked ordinary dividend for the quarter ending June 2025, accompanied by a dividend reinvestment plan offering a 2% discount.

Turners Automotive Group has declared a higher Q1 FY26 dividend of 7 cents per share, up from 6 cents last year, reflecting steady financial health and shareholder returns.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.